Cardionomic, based in Minneapolis, is developing a catheter-based neuromodulation therapy to treat Acute Decompensated Heart Failure (ADHF). The therapy selectively stimulates cardiac nerve branches to increase myocardial contractility and rebalance hemodynamics, aiming to address the root cause of ADHF rather than only relieve symptoms. It is intended to be delivered on patient admission and remain in place for one to three days before removal. Company leaders cite extensive pre-clinical and human data gathered over the past three years showing improved contractility in heart failure patients. Cardionomic will use the new funding to continue development of the therapy for ADHF, a condition that drives significant hospital admissions, readmissions, and healthcare costs. The article positions this raise as the company’s successful first round of financing.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2015